Original from: Castle Biosciences
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed.
“This proposed transaction underscores our commitment to the gastrointestinal (GI) community-providers and patients,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Our growth initiatives include the continual assessment of complementary technologies. With Previse, we found an opportunity to expand our offerings within our GI vertical, beyond our spatialomics TissueCypher Barrett’s Esophagus test, allowing us to offer customers a more robust set of testing options. Previse’s methylation technology, as well as its pipeline technologies, provide us with the potential to address existing unmet needs, including potential upstream opportunities.”
“We are excited about joining Castle,” said Daniel Lunz, chief executive officer of Previse. “We look forward to the advancements to care we can make together for patients with GI diseases-our technologies, combined with Castle’s TissueCypher test and history of executional success.”
The transaction is expected to close in the coming weeks, subject to the customary closing conditions.
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.